Compositions and methods for treating retinal degradation

Patent metadata

Field	Value
Publication number	US-10300057-B2
Application number	US-201615142087-A
Country	US
Kind code	B2
Filing date	Apr 29, 2016
Priority date	Aug 1, 2013
Publication date	May 28, 2019
Grant date	May 28, 2019

Abstract

The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.

First claim

What is claimed is:

1. A method for treating rheumatoid arthritis, comprising:
administering an effective amount of a composition to a subject in need thereof, wherein the composition comprises a pharmaceutically acceptable carrier and a compound selected from:
(i) a compound having the structure of

or a pharmaceutically acceptable salt thereof;
(ii) a compound having the structure of

or a pharmaceutically acceptable salt thereof;
(iii) stavudine (d4T);
(iv) azidothymidine (AZT);
(v) abacavir (ABC); and
(vi) a combination thereof.

2. The method of claim 1 , comprising inhibiting inflammasome activation by Alu RNA associated with a cell.

3. The method of claim 1 , comprising reducing ATP-induced permeability of a cell.

4. The method of claim 1 , comprising reducing an amount of mitochondrial reactive oxygen species in a cell.

5. The method of claim 2 , wherein the inflammasome is selected from an NLRP3 inflammasome, an IL-1beta inflammasome, and a combination thereof.

6. A method for treating diabetes, comprising:
administering an effective amount of a composition to a subject in need thereof, wherein the composition comprises a pharmaceutically acceptable carrier and a compound selected from:
(i) a compound having the structure of

or a pharmaceutically acceptable salt thereof;
(ii) a compound having the structure of

or a pharmaceutically acceptable salt thereof;
(iii) stavudine (d4T);
(iv) lamivudine (3TC);
(v) cordycepin;
(vi) azidothymidine (AZT);
(vii) abacavir (ABC); and
(viii) a combination thereof.

7. The method of claim 6 , comprising inhibiting inflammasome activation by Alu RNA associated with a cell.

8. The method of claim 7 , wherein the inflammasome is selected from an NLRP3 inflammasome, an IL-1beta inflammasome, and a combination thereof.

9. The method of claim 6 , comprising reducing ATP-induced permeability of a cell.

10. The method of claim 6 , comprising reducing an amount of mitochondrial reactive oxygen species in a cell.

11. The method of claim 6 , wherein the diabetes is type 2 diabetes.

12. The method of claim 1 , wherein the compound is selected from (i), (iii), (iv), and (v).

13. The method of claim 1 , wherein the compound is selected from (i) and (ii).

14. The method of claim 1 , wherein the compound is (i).

Assignees

• Univ Kentucky Res Found

Inventors

• Ambati Jayakrishna
• Fowler Benjamin

Classifications

• A61K31/7072

  having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine · CPC title

• A61K31/7064

  containing condensed or non-condensed pyrimidines · CPC title

• A61K31/7076

  containing purines, e.g. adenosine, adenylic acid · CPC title

• A61K31/513

  having oxo groups directly attached to the heterocyclic ring, e.g. cytosine · CPC title

• A61K31/506 Primary

  not condensed and containing further heterocyclic rings · CPC title